AstraZeneca makes RNA play, teaming up with startup to advance twist on red-hot modality

AstraZeneca is making a play for the red-hot RNA market. Rather than move directly onto turf fought over by the likes of BioNTech, Moderna and Sanofi, AstraZeneca has teamed up with a new British startup that has put a twist on the idea of using nucleic acids to trigger production of a molecule.